Can a PET scan predict lung cancer treatment success after just one dose?
NCT ID NCT03832348
First seen Jan 06, 2026 · Last updated May 19, 2026 · Updated 13 times
Summary
This study looked at 40 people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. They received the immunotherapy drug pembrolizumab, and researchers used PET scans after the first dose to see if early changes in tumor activity could predict whether the treatment would work after 3 months. The goal was to learn how tumors respond early on, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU
Rouen, 76000, France
-
Centre Henri Becquerel
Rouen, 76000, France
Conditions
Explore the condition pages connected to this study.